Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) provided updates on its pipeline and business operations before the 42nd Annual J.P. Morgan Healthcare Conference. Key highlights include the launch of CASGEVY in the U.S., UK, and Bahrain, completion of pivotal studies for cystic fibrosis treatments, and progress in studies for sickle cell disease, acute pain, peripheral neuropathic pain, kidney disease, type 1 diabetes, and myotonic dystrophy. Vertex also revised patient estimates for cystic fibrosis and sickle cell disease. The company expects to share study results and advance various programs in 2024.